The IPO of Lianying medical technology innovation board has been accepted by Shanghai Stock Exchange
The IPO application of Lianying medical technology innovation board has been accepted by Shanghai Stock Exchange. In January 2021, the website of Shanghai Securities Regulatory Bureau disclosed that Lianying medical signed a listing guidance agreement and officially launched the listing process of the science and innovation board. CITIC Securities and CICC jointly served as the guidance agency.
This text is a result of machine translation.
Briefing May 17, 2022 10:54 AM
· Healthcare
Heavy bomb in the field of hypoglycemic! Lilly tirzepatide approved for listing
In-depth
Financials, Healthcare
Exclusive Interview with Zhou Mi, Managing Partner of Puhua Capital
“I entered the venture capital industry in 2008. I experienced the financial crisis in 2009 and the boom of the classical venture capital model from 2011 to 2015. Having experienced many ups and downs, I believe that venture capital will tide over the tough period and usher in new opportunities.”
May 12, 2022 05:41 PM
Briefing May 11, 2022 03:53 PM
· Healthcare
Roche PD-L1 combined with tigit failed in the first-line treatment of stage III non-small cell lung cancer with high expression of PD-L1
Briefing May 11, 2022 02:46 PM
· Healthcare
Foreign media said Green Valley pharmaceutical Alzheimer's disease new drug phase IX phase I ® The international phase III clinical trial has been stopped
Apr 18, 2022 06:30 PM
Apr 22, 2021 03:11 PM
Research
Healthcare, Consumer Staples, TechnologyWIA2020 | Rising Tech Stars 2020: Global & China's 100
Dec 09, 2020 09:57 AM
Dec 09, 2020 09:39 AM
Briefing May 11, 2022 02:18 PM
· Healthcare
The new drug registration of step pharmaceutical subsidiary was terminated, and 7.6 million R & D expenses have been invested
Briefing May 10, 2022 09:32 PM
· Healthcare
Pfizer acquired biohaven for about US $11.6 billion to expand the product pipeline of nervous system diseases
Briefing May 10, 2022 05:23 PM
· Healthcare
Beijing will carry out data collection standardization pilot in the field of digital medicine
Healthcare
Nucleic Acid Drug CDMO Olipharma Raises Tens of Mns of CNY in Pre-Series A Round
As a new way to treat diseases, gene therapy has higher R&D investment and risk than biochemical drugs. Both pharmaceutical giants and start-ups tend to collaborate with outsourcing service providers, which brings business opportunities to cell and gene therapy contract development and manufacturing organizations (CDMOs).
Yesterday 09:59 PM
Briefing Apr 27, 2022 06:47 PM
· Healthcare
Medtronic's world's first self expanding pulmonary valve was first-class recalled
Briefing Apr 26, 2022 07:38 PM
· Healthcare
Yikai capital released the first set of digital collections of Chinese investment and financing institutions
Briefing Apr 26, 2022 03:52 PM
· Healthcare
Inactivated vaccine against novel coronavirus of Chinese medicine Zhongsheng Omicron mutant approved for clinical use
Financials, Healthcare
Cell Therapy Developer Senlang Bio Raises CNY 200 Million in New Funding Round
Founded in 2016, Hebei Senlang Bio is a clinical-stage biotechnology company dedicated to utilizing cell and gene engineering technologies to generate innovative and transformative cellular immunotherapies for solid and hematologic cancers.
Yesterday 01:00 PM
Briefing Apr 26, 2022 03:43 PM
· Healthcare
The new crown inactivated vaccine of Sinopharm Zhongsheng Omicron mutant was approved clinically.
Briefing Apr 26, 2022 11:20 AM
· Healthcare
Yanye said that its Xinguan oral drug s-217622 can quickly eliminate the virus
Briefing Apr 26, 2022 11:11 AM
· Healthcare
Bojian abandons Alzheimer's disease drug aduhelm and goes public in the EU
Briefing Apr 25, 2022 06:13 PM
· Healthcare
Baiyang pharmaceutical released its first annual report after listing, with double growth in revenue and net profit in 2021
See more
Read next
In-depth
In-depth
In-depth
Financials, Healthcare
Exclusive Interview with Zhou Mi, Managing Partner of Puhua Capital
May 12, 2022 05:41 PM
EqualOcean is an information service provider and investment research company that aims to become a global platform for industrial innovation. Founded in February 2014 and headquartered in Beijing, with a client network covering over 50 countries, the firm provides comprehensive professional services, including industry research, investment analysis, innovation consulting, data products, corporate branding and international strategy.